Ilva D. Rupenthal

4.8k total citations · 1 hit paper
120 papers, 3.7k citations indexed

About

Ilva D. Rupenthal is a scholar working on Molecular Biology, Pharmaceutical Science and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ilva D. Rupenthal has authored 120 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 47 papers in Pharmaceutical Science and 46 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ilva D. Rupenthal's work include Ocular Surface and Contact Lens (46 papers), Advanced Drug Delivery Systems (41 papers) and Connexins and lens biology (32 papers). Ilva D. Rupenthal is often cited by papers focused on Ocular Surface and Contact Lens (46 papers), Advanced Drug Delivery Systems (41 papers) and Connexins and lens biology (32 papers). Ilva D. Rupenthal collaborates with scholars based in New Zealand, Australia and Germany. Ilva D. Rupenthal's co-authors include Colin Green, Priyanka Agarwal, Ying-Shan Chen, Rohit Bisht, Abhirup Mandal, Di Huang, Odunayo O. Mugisho, Ashim K. Mitra, Mónica L. Acosta and Raid G. Alany and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biomaterials.

In The Last Decade

Ilva D. Rupenthal

117 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies

2017 365 citations Ilva D. Rupenthal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ilva D. Rupenthal New Zealand	36	1.4k	1.3k	1.1k	884	772	120	3.7k
Rocío Herrero‐Vanrell Spain	33	736 0.5×	1.0k 0.8×	1.1k 0.9×	1.0k 1.2×	871 1.1×	120	3.0k
Yolanda Diebold Spain	29	672 0.5×	966 0.8×	1.5k 1.4×	605 0.7×	955 1.2×	85	3.1k
Armando Silva‐Cunha Brazil	27	780 0.6×	666 0.5×	416 0.4×	561 0.6×	385 0.5×	151	2.6k
Amélie Bochot France	34	1.2k 0.9×	1.3k 1.0×	415 0.4×	386 0.4×	350 0.5×	73	3.5k
Abhirup Mandal United States	20	630 0.5×	788 0.6×	550 0.5×	364 0.4×	420 0.5×	29	2.3k
Sara Nicoli Italy	32	813 0.6×	1.6k 1.3×	534 0.5×	229 0.3×	257 0.3×	100	3.5k
Sangly P. Srinivas United States	32	1.1k 0.8×	289 0.2×	456 0.4×	546 0.6×	620 0.8×	97	2.8k
Irene T. Molina‐Martínez Spain	26	454 0.3×	628 0.5×	635 0.6×	462 0.5×	410 0.5×	71	1.8k
Vibhuti Agrahari United States	19	754 0.6×	436 0.3×	335 0.3×	290 0.3×	290 0.4×	33	1.8k
Ching‐Li Tseng Taiwan	26	488 0.4×	382 0.3×	488 0.4×	231 0.3×	425 0.6×	90	2.2k

Countries citing papers authored by Ilva D. Rupenthal

Since Specialization

Citations

This map shows the geographic impact of Ilva D. Rupenthal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilva D. Rupenthal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilva D. Rupenthal more than expected).

Fields of papers citing papers by Ilva D. Rupenthal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilva D. Rupenthal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilva D. Rupenthal. The network helps show where Ilva D. Rupenthal may publish in the future.

Co-authorship network of co-authors of Ilva D. Rupenthal

This figure shows the co-authorship network connecting the top 25 collaborators of Ilva D. Rupenthal. A scholar is included among the top collaborators of Ilva D. Rupenthal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilva D. Rupenthal. Ilva D. Rupenthal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rupenthal, Ilva D., et al.. (2025). Evaluation of ocular tolerability and bioavailability of tonabersat transfersomes ex vivo. Drug Delivery and Translational Research. 16(4). 1222–1232. 1 indexed citations

Agarwal, Priyanka, et al.. (2025). Influence of tear fluid properties on physicochemical, mucoadhesion and ocular penetration characteristics of transfersomes. European Journal of Pharmaceutics and Biopharmaceutics. 212. 114745–114745. 1 indexed citations

Rupenthal, Ilva D., et al.. (2025). The NLRP3 inflammasome pathway contributes to chronic inflammation in experimental autoimmune uveitis. Animal Models and Experimental Medicine. 8(6). 1080–1094.

Rupenthal, Ilva D., Liu Li, Yuexian Hong, et al.. (2025). Enhanced ocular retention and intraocular pressure-lowering efficacy of hydrophobic microspheres for glaucoma treatment. Colloids and Surfaces B Biointerfaces. 252. 114659–114659.

Brugger, Stefan, et al.. (2024). Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations. Pharmaceutics. 16(10). 1302–1302. 8 indexed citations

Brugger, Stefan, et al.. (2024). Development of transferosomes for topical ocular drug delivery of curcumin. European Journal of Pharmaceutics and Biopharmaceutics. 205. 114535–114535. 15 indexed citations

Agarwal, Priyanka, et al.. (2023). Preclinical characterization of water-free cyclosporine eye drops – Factors impacting ocular penetration ex vivo and in vivo. European Journal of Pharmaceutics and Biopharmaceutics. 188. 100–107. 5 indexed citations

Mugisho, Odunayo O., et al.. (2023). Comprehensive Grading System for Experimental Autoimmune Uveitis in Mice. Biomedicines. 11(7). 2022–2022. 4 indexed citations

Mugisho, Odunayo O., et al.. (2023). Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences. 24(4). 3876–3876. 12 indexed citations

10.

Marasini, Sanjay, S. Dean, Simon Swift, et al.. (2022). Preclinical confirmation of UVC efficacy in treating infectious keratitis. The Ocular Surface. 25. 76–86. 11 indexed citations

11.

Rupenthal, Ilva D., et al.. (2021). Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases. International Journal of Molecular Sciences. 22(4). 1755–1755. 11 indexed citations

12.

Kang, Heather, et al.. (2020). The influence of hyperglycemia on the safety of ultrasound in retinal pigment epithelial cells. Cell Biology International. 45(3). 558–568. 2 indexed citations

13.

Mugisho, Odunayo O., Colin Green, Jie Zhang, Mónica L. Acosta, & Ilva D. Rupenthal. (2019). Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy. Drug Discovery Today. 24(8). 1627–1636. 22 indexed citations

14.

Mugisho, Odunayo O., Ilva D. Rupenthal, François Paquet‐Durand, Mónica L. Acosta, & Colin Green. (2019). Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease. Expert Opinion on Therapeutic Targets. 23(10). 855–863. 37 indexed citations

15.

Rupenthal, Ilva D., et al.. (2019). Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease. Neurotherapeutics. 17(1). 371–387. 47 indexed citations

16.

Green, Colin, et al.. (2019). Connexin hemichannel block shuts down inflammation in an animal model of chronic diabetic retinopathy to improve structural and functional outcomes. Investigative Ophthalmology & Visual Science. 60(9). 2784–2784. 2 indexed citations

17.

Sharma, Manisha, Zaid Aqrawe, Ilva D. Rupenthal, et al.. (2018). Micelle directed chemical polymerization of polypyrrole particles for the electrically triggered release of dexamethasone base and dexamethasone phosphate. International Journal of Pharmaceutics. 543(1-2). 38–45. 24 indexed citations

18.

Mugisho, Odunayo O., Ilva D. Rupenthal, David Squirrell, et al.. (2018). Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathy. PLoS ONE. 13(8). e0202156–e0202156. 39 indexed citations

19.

Mugisho, Odunayo O., Colin Green, David Squirrell, et al.. (2018). Intravitreal pro-inflammatory cytokines induce signs of diabetic retinopathy in non-obese diabetic mice. Investigative Ophthalmology & Visual Science. 59(9). 5358–5358. 3 indexed citations

20.

Rupenthal, Ilva D., et al.. (2015). Ocular delivery systems for topical application of anti-infective agents. Drug Development and Industrial Pharmacy. 42(1). 1–11. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact